Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

NCT04247282 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

21

Enrollment

NIH

Sponsor class

Conditions

Head and Neck Cancer
Head and Neck Neoplasms

Interventions

DRUG: M7824
DRUG: N803
BIOLOGICAL: TriAd vaccine

Sponsor

National Cancer Institute (NCI)